Examples include the METTL3 inhibitor STM2457 in AML (61) and cervical cancer (14), as well as CS1 and CS2 in AML (62) and the FTO inhibitor 18097 in breast cancer (63). This evidence concerns the gene FTO and cervical carcinoma.